MeSH term
Frequency | Condition_Probility | Female | 298 | 0.0 |
Humans | 637 | 0.0 |
Pregnancy | 10 | 0.0 |
Randomized Controlled Trials | 3 | 0.0 |
Cell Culture Techniques | 2 | 0.0 |
Cell Differentiation/*physiology | 2 | 0.0 |
Adult | 81 | 0.0 |
Child | 15 | 0.0 |
Male | 82 | 0.0 |
Cluster Analysis | 4 | 2.0 |
Genes, erbB-2 | 27 | 33.0 |
*Genetic Markers | 4 | 1.0 |
In Situ Hybridization, Fluorescence | 31 | 1.0 |
Nucleic Acid Hybridization/methods | 2 | 2.0 |
Prognosis | 57 | 0.0 |
Research Support, Non-U.S. Gov't | 420 | 0.0 |
Tumor Markers, Biological/genetics/metabolism | 2 | 12.0 |
1-Phosphatidylinositol 3-Kinase/metabolism | 9 | 1.0 |
Breast Neoplasms/metabolism | 5 | 4.0 |
Enzyme Activation | 28 | 0.0 |
*Gene Expression Regulation | 5 | 0.0 |
Mitogen-Activated Protein Kinases/metabolism | 21 | 2.0 |
Neuregulin-1/*physiology | 2 | 22.0 |
Receptor, erbB-2/*metabolism | 60 | 39.0 |
Research Support, U.S. Gov't, P.H.S. | 199 | 0.0 |
Tumor Cells, Cultured | 163 | 0.0 |
Adenocarcinoma/*metabolism | 2 | 2.0 |
Animals | 204 | 0.0 |
Blotting, Western | 40 | 0.0 |
Breast Neoplasms/*metabolism | 19 | 6.0 |
*Drug Resistance, Neoplasm | 4 | 2.0 |
Immunoenzyme Techniques | 17 | 0.0 |
Precipitin Tests | 22 | 0.0 |
Rats | 37 | 0.0 |
Receptor, erbB-2/*immunology | 8 | 47.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 62 | 0.0 |
Transfection | 65 | 0.0 |
Aged | 76 | 0.0 |
Breast Neoplasms/*metabolism/pathology | 4 | 2.0 |
Comparative Study | 77 | 0.0 |
Disease-Free Survival | 12 | 1.0 |
Lymph Nodes/pathology | 2 | 0.0 |
Lymphatic Metastasis | 10 | 0.0 |
Middle Aged | 98 | 0.0 |
Vascular Endothelial Growth Factor A | 6 | 0.0 |
Administration, Oral | 2 | 0.0 |
Aged, 80 and over | 36 | 0.0 |
Disease Progression | 11 | 0.0 |
Receptor, Epidermal Growth Factor/metabolism | 31 | 5.0 |
Receptor, erbB-2/metabolism | 41 | 25.0 |
Receptors, Estrogen/*metabolism | 4 | 1.0 |
Receptors, Progesterone/metabolism | 7 | 3.0 |
Cell Adhesion | 7 | 0.0 |
Cell Division | 26 | 0.0 |
DNA Primers/chemistry | 4 | 0.0 |
Fibroblasts/metabolism | 4 | 0.0 |
Immunoblotting | 17 | 0.0 |
Mutagenesis, Site-Directed | 8 | 0.0 |
Phosphorylation | 94 | 1.0 |
Plasmids | 3 | 0.0 |
Polymerase Chain Reaction | 22 | 0.0 |
Receptor, Epidermal Growth Factor/genetics/*physiology | 2 | 6.0 |
Receptor, erbB-2/genetics/*physiology | 4 | 57.0 |
Retroviridae/genetics | 7 | 1.0 |
Signal Transduction | 52 | 0.0 |
Tyrosine/metabolism | 26 | 2.0 |
*Chromosome Mapping | 8 | 0.0 |
Chromosomes, Human, Pair 17/*genetics | 6 | 3.0 |
Genes, erbB-2/genetics | 8 | 30.0 |
Neoplasm Invasiveness/genetics | 3 | 6.0 |
Neoplasm Staging | 24 | 1.0 |
Survival Analysis | 13 | 0.0 |
Amino Acid Sequence | 44 | 0.0 |
Epithelium/metabolism | 5 | 1.0 |
Ligands | 48 | 1.0 |
Models, Biological | 7 | 0.0 |
Molecular Sequence Data | 61 | 0.0 |
Mucins/genetics/*metabolism | 2 | 5.0 |
Sequence Homology, Amino Acid | 19 | 0.0 |
Chromatography, Liquid | 2 | 1.0 |
Sensitivity and Specificity | 9 | 0.0 |
Antigens, CD44/metabolism | 2 | 2.0 |
Cell Division/drug effects | 39 | 1.0 |
Gene Expression Regulation/drug effects | 3 | 0.0 |
Phosphorylation/drug effects | 15 | 1.0 |
Receptor, Epidermal Growth Factor/*physiology | 5 | 3.0 |
1-Phosphatidylinositol 3-Kinase/*metabolism | 4 | 1.0 |
Cell Cycle Proteins/metabolism | 4 | 1.0 |
Cyclins/metabolism | 3 | 0.0 |
Enzyme Inhibitors/pharmacology | 20 | 0.0 |
Epidermal Growth Factor/pharmacology | 18 | 2.0 |
Flow Cytometry | 14 | 0.0 |
Mitogen-Activated Protein Kinases/*metabolism | 4 | 0.0 |
Neuregulin-1/pharmacology | 7 | 46.0 |
Signal Transduction/drug effects | 8 | 1.0 |
Time Factors | 28 | 0.0 |
p38 Mitogen-Activated Protein Kinases | 6 | 0.0 |
Mice | 113 | 0.0 |
Mice, Mutant Strains | 3 | 0.0 |
*Mutation | 4 | 0.0 |
Biopsy | 6 | 0.0 |
English Abstract | 17 | 0.0 |
Multigene Family | 4 | 0.0 |
*Oligonucleotide Array Sequence Analysis | 7 | 3.0 |
Tumor Markers, Biological | 9 | 2.0 |
Antibodies, Monoclonal/*therapeutic use | 6 | 1.0 |
Bacteriophages/genetics | 2 | 8.0 |
Cloning, Molecular | 16 | 0.0 |
Endocytosis | 5 | 1.0 |
Antineoplastic Agents, Phytogenic/*pharmacology | 3 | 1.0 |
*Apoptosis | 5 | 0.0 |
Breast Neoplasms/metabolism/pathology | 2 | 5.0 |
CDC2 Protein Kinase/*metabolism | 3 | 2.0 |
Cells, Cultured | 35 | 0.0 |
Cyclin B/metabolism | 3 | 3.0 |
DNA Fragmentation | 3 | 0.0 |
Drug Resistance, Neoplasm | 8 | 1.0 |
In Situ Nick-End Labeling | 2 | 0.0 |
Mitosis | 4 | 0.0 |
Paclitaxel/*pharmacology | 5 | 7.0 |
Tyrosine/*metabolism | 4 | 1.0 |
Cell Line | 65 | 0.0 |
Dogs | 6 | 0.0 |
Protein Binding | 32 | 0.0 |
Antibodies, Monoclonal/pharmacology | 6 | 0.0 |
Antineoplastic Agents/*pharmacology | 9 | 0.0 |
Epidermal Growth Factor/*pharmacology | 6 | 0.0 |
G1 Phase/drug effects | 2 | 1.0 |
Growth Substances/pharmacology | 3 | 1.0 |
*Intercellular Signaling Peptides and Proteins | 8 | 1.0 |
*Protein-Serine-Threonine Kinases | 18 | 2.0 |
Proto-Oncogene Proteins/metabolism | 20 | 1.0 |
Pyrimidines/*pharmacology | 2 | 3.0 |
Pyrroles/*pharmacology | 2 | 4.0 |
Receptor, Epidermal Growth Factor/*antagonists & inhibitors | 8 | 6.0 |
Receptor, erbB-2/*antagonists & inhibitors | 6 | 40.0 |
Signal Transduction/drug effects/physiology | 3 | 1.0 |
Substrate Specificity | 4 | 0.0 |
Dimerization | 27 | 1.0 |
Intercellular Signaling Peptides and Proteins/pharmacology | 2 | 7.0 |
Receptor, Epidermal Growth Factor/*metabolism | 37 | 4.0 |
Receptor, erbB-2/*physiology | 9 | 36.0 |
Receptor, erbB-3/*physiology | 2 | 40.0 |
Blotting, Northern | 19 | 0.0 |
*DNA-Binding Proteins | 3 | 0.0 |
*Gene Expression Regulation, Neoplastic | 19 | 1.0 |
Promoter Regions (Genetics) | 10 | 0.0 |
Proto-Oncogene Proteins/*biosynthesis/genetics | 3 | 3.0 |
Reverse Transcriptase Polymerase Chain Reaction | 43 | 0.0 |
Transcription, Genetic | 13 | 0.0 |
Drug Design | 3 | 0.0 |
Kinetics | 21 | 0.0 |
Models, Molecular | 13 | 0.0 |
Protein Conformation | 9 | 0.0 |
Receptor, erbB-2/chemistry/metabolism | 2 | 66.0 |
Receptor, erbB-3/chemistry/metabolism | 2 | 100.0 |
Immunohistochemistry/methods | 7 | 1.0 |
Neoplasm Proteins/*analysis | 2 | 0.0 |
Pedigree | 3 | 0.0 |
Proportional Hazards Models | 7 | 1.0 |
Receptor, erbB-2/*analysis | 11 | 13.0 |
Amino Acid Motifs | 4 | 0.0 |
Amino Acids/chemistry | 4 | 3.0 |
COS Cells | 12 | 0.0 |
Glutamic Acid/chemistry | 3 | 8.0 |
Mutation | 20 | 0.0 |
Protein Structure, Tertiary | 18 | 0.0 |
Trans-Activation (Genetics) | 5 | 0.0 |
Valine/chemistry | 2 | 9.0 |
Breast Neoplasms/genetics | 5 | 2.0 |
Doxorubicin/pharmacology | 4 | 1.0 |
Gene Amplification | 38 | 5.0 |
*Genes, erbB-2 | 43 | 50.0 |
Mice, Knockout | 7 | 0.0 |
Receptor, Epidermal Growth Factor/genetics | 11 | 9.0 |
Gene Dosage | 14 | 3.0 |
Gene Expression Profiling | 11 | 1.0 |
Oligonucleotide Array Sequence Analysis | 17 | 1.0 |
Stomach Neoplasms/*genetics/metabolism | 2 | 7.0 |
Cell Transformation, Neoplastic | 7 | 1.0 |
*Gene Amplification | 32 | 8.0 |
Gene Expression Regulation, Neoplastic | 38 | 1.0 |
*Neoplasm Invasiveness | 3 | 4.0 |
Receptor, Epidermal Growth Factor | 2 | 0.0 |
Receptor, erbB-2/*biosynthesis | 17 | 34.0 |
Antibiotics, Antineoplastic/*pharmacology | 4 | 3.0 |
Clinical Trials | 8 | 0.0 |
Growth Inhibitors/pharmacology | 2 | 1.0 |
Heat-Shock Proteins 90/*antagonists & inhibitors | 5 | 41.0 |
Protein Kinases/metabolism | 4 | 0.0 |
Quinones/*pharmacology | 5 | 16.0 |
Receptors, Growth Factor/*metabolism | 3 | 2.0 |
Transcription Factors/metabolism | 6 | 0.0 |
Gene Expression | 25 | 0.0 |
Receptor, erbB-2/genetics/metabolism | 5 | 33.0 |
Chromosomes, Human, Pair 17/genetics | 7 | 4.0 |
RNA, Messenger/biosynthesis/genetics | 4 | 0.0 |
Up-Regulation | 11 | 0.0 |
3T3 Cells | 16 | 0.0 |
Antineoplastic Combined Chemotherapy Protocols/*pharmacology | 3 | 6.0 |
Breast Neoplasms/drug therapy/metabolism | 3 | 33.0 |
Cell Survival/drug effects | 8 | 0.0 |
Drug Synergism | 9 | 0.0 |
*Proto-Oncogene Proteins | 8 | 0.0 |
Breast Neoplasms/*pathology | 9 | 4.0 |
Cell Cycle | 10 | 0.0 |
Phenotype | 12 | 0.0 |
Immunohistochemistry | 61 | 0.0 |
Receptor, erbB-3/*metabolism | 6 | 28.0 |
Heat-Shock Proteins 90/metabolism | 2 | 6.0 |
Lung Neoplasms/genetics/*metabolism | 2 | 11.0 |
Mitogen-Activated Protein Kinase 1/metabolism | 6 | 1.0 |
Protein-Serine-Threonine Kinases/metabolism | 4 | 0.0 |
RNA, Messenger/metabolism | 20 | 0.0 |
Receptor, Epidermal Growth Factor/genetics/*metabolism | 10 | 6.0 |
Receptor, erbB-2/genetics/*metabolism | 14 | 42.0 |
Tumor Cells, Cultured/drug effects | 7 | 1.0 |
Antibiotics, Antineoplastic/*therapeutic use | 2 | 8.0 |
Protein-Tyrosine Kinase/antagonists & inhibitors | 2 | 0.0 |
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use | 6 | 1.0 |
Breast Neoplasms/*drug therapy/metabolism/pathology | 4 | 28.0 |
Collagen | 3 | 1.0 |
Cyclophosphamide/administration & dosage | 3 | 1.0 |
Drug Screening Assays, Antitumor | 7 | 2.0 |
Epirubicin/administration & dosage | 2 | 5.0 |
Gels | 2 | 2.0 |
Predictive Value of Tests | 11 | 0.0 |
*Taxoids | 2 | 3.0 |
Tumor Markers, Biological/metabolism | 4 | 1.0 |
Adolescent | 14 | 0.0 |
Neoplasm Metastasis | 18 | 1.0 |
Antineoplastic Agents/*therapeutic use | 5 | 1.0 |
Drug Therapy, Combination | 2 | 0.0 |
Estrogen Antagonists/*therapeutic use | 3 | 15.0 |
Tamoxifen/*therapeutic use | 6 | 7.0 |
Antigens, CD44/*metabolism | 2 | 1.0 |
Microscopy, Confocal | 7 | 0.0 |
Gene Expression Regulation, Neoplastic/*physiology | 4 | 2.0 |
Metaplasia | 2 | 2.0 |
Receptor, Epidermal Growth Factor/analysis | 6 | 3.0 |
Receptor, erbB-3/*analysis | 2 | 40.0 |
Signal Transduction/physiology | 10 | 1.0 |
Child, Preschool | 8 | 0.0 |
Infant | 4 | 0.0 |
Mice, Nude | 18 | 0.0 |
Neoplasm Transplantation | 15 | 1.0 |
Receptor, erbB-2/*genetics | 18 | 48.0 |
Enzyme Inhibitors/*chemical synthesis/pharmacology | 3 | 16.0 |
Proto-Oncogene Proteins/*antagonists & inhibitors | 2 | 8.0 |
Structure-Activity Relationship | 10 | 0.0 |
Cercopithecus aethiops | 3 | 0.0 |
Neuregulins/*metabolism | 3 | 75.0 |
Proteins/genetics/*metabolism | 2 | 0.0 |
Receptor, erbB-3/genetics/*metabolism | 2 | 66.0 |
*Chromosome Aberrations | 9 | 1.0 |
Dogs/*genetics | 2 | 4.0 |
Cell Differentiation | 5 | 0.0 |
Signal Transduction/*genetics | 4 | 3.0 |
Apoptosis/physiology | 2 | 0.0 |
Cell Movement/*physiology | 3 | 1.0 |
Cell Survival/*physiology | 2 | 3.0 |
Receptor Protein-Tyrosine Kinases/metabolism | 4 | 1.0 |
Down-Regulation | 18 | 0.0 |
RNA, Messenger/analysis | 12 | 0.0 |
Receptor, Epidermal Growth Factor/analysis/*genetics | 2 | 9.0 |
Binding, Competitive | 7 | 0.0 |
Dose-Response Relationship, Drug | 15 | 0.0 |
Enzyme-Linked Immunosorbent Assay | 6 | 0.0 |
Gene Library | 2 | 0.0 |
Glutathione Transferase/metabolism | 2 | 0.0 |
Recombinant Fusion Proteins/metabolism | 5 | 0.0 |
src Homology Domains | 5 | 0.0 |
Adenocarcinoma/genetics/metabolism/pathology | 2 | 6.0 |
Antibodies/immunology | 4 | 1.0 |
Breast Neoplasms/genetics/metabolism/pathology | 3 | 10.0 |
*Cell Movement | 2 | 1.0 |
Apoptosis/*drug effects | 4 | 0.0 |
Breast Neoplasms/pathology | 6 | 5.0 |
Enzyme Inhibitors/*pharmacology | 9 | 1.0 |
Gene Expression Regulation | 12 | 0.0 |
Heat-Shock Proteins 90/*metabolism | 3 | 12.0 |
Mice, Inbred BALB C | 5 | 0.0 |
Breast Neoplasms | 12 | 4.0 |
Cell Membrane/metabolism | 6 | 0.0 |
Cytosol/metabolism | 2 | 0.0 |
Protein Transport | 2 | 0.0 |
Recombinant Proteins/metabolism | 8 | 0.0 |
Breast Neoplasms/genetics/metabolism | 3 | 6.0 |
*Gene Dosage | 4 | 4.0 |
*Gene Expression | 8 | 0.0 |
Genes, erbB-2/*genetics | 14 | 37.0 |
Androstadienes/pharmacology | 4 | 1.0 |
Binding Sites | 20 | 0.0 |
Neuregulin-1/metabolism | 4 | 30.0 |
Oncogene Proteins v-erbB/metabolism | 5 | 55.0 |
Phosphoproteins/genetics/*metabolism | 2 | 1.0 |
Proto-Oncogene Proteins/*metabolism | 13 | 1.0 |
Breast Neoplasms/diagnosis/genetics/*metabolism | 2 | 40.0 |
Cyclin D1/biosynthesis/genetics | 3 | 15.0 |
Estrogen Receptor alpha | 9 | 3.0 |
Protein Biosynthesis | 4 | 0.0 |
Proteins/genetics | 3 | 0.0 |
Proto-Oncogene Proteins c-myc/biosynthesis/genetics | 2 | 11.0 |
RNA, Neoplasm/biosynthesis | 2 | 1.0 |
Receptor, erbB-2/biosynthesis/genetics | 8 | 40.0 |
Receptors, Estrogen/*biosynthesis/genetics | 2 | 33.0 |
Cycloheximide/pharmacology | 3 | 0.0 |
*Genes, erbB | 5 | 45.0 |
Insulin/*pharmacology | 2 | 0.0 |
MAP Kinase Signaling System | 4 | 1.0 |
Neuregulin-1/physiology | 2 | 50.0 |
*Trans-Activation (Genetics) | 4 | 0.0 |
Tumor Necrosis Factor-alpha/*pharmacology | 3 | 0.0 |
Genes, erbB | 6 | 75.0 |
*Receptor, erbB-2 | 3 | 100.0 |
Receptor, erbB-3 | 27 | 31.0 |
Alternative Splicing | 3 | 0.0 |
DNA, Complementary/genetics | 3 | 0.0 |
Peptide Mapping | 2 | 0.0 |
Protein Isoforms | 7 | 1.0 |
Cell Cycle/drug effects | 7 | 1.0 |
Receptor, erbB-2/*biosynthesis/metabolism | 2 | 100.0 |
Xenograft Model Antitumor Assays | 7 | 3.0 |
DNA-Binding Proteins/biosynthesis/genetics | 2 | 2.0 |
Pancreatic Neoplasms/genetics/*metabolism/pathology | 2 | 16.0 |
Protein p53/biosynthesis/genetics | 4 | 8.0 |
Antibiotics, Antineoplastic/pharmacology | 3 | 3.0 |
Cell Survival | 2 | 0.0 |
Chromones/pharmacology | 5 | 2.0 |
Cyclin E/metabolism | 2 | 1.0 |
Genes, Dominant | 3 | 0.0 |
Morpholines/pharmacology | 5 | 2.0 |
Sirolimus/pharmacology | 2 | 2.0 |
Neoplasms, Experimental/*drug therapy/pathology | 2 | 22.0 |
Quinazolines/*pharmacology/therapeutic use | 2 | 33.0 |
Cell Division/*drug effects | 3 | 1.0 |
Plasmids/genetics | 4 | 0.0 |
Cell Membrane/*metabolism | 3 | 1.0 |
DNA Mutational Analysis | 3 | 0.0 |
Genetic Vectors | 6 | 0.0 |
Receptor, Epidermal Growth Factor/*chemistry | 2 | 13.0 |
Antineoplastic Agents/pharmacology | 9 | 1.0 |
Butadienes/pharmacology | 2 | 3.0 |
Cell Division/physiology | 7 | 0.0 |
MAP Kinase Signaling System/*physiology | 3 | 3.0 |
Microscopy, Fluorescence | 8 | 0.0 |
Mitogen-Activated Protein Kinase 7 | 2 | 13.0 |
Nitriles/pharmacology | 2 | 1.0 |
Phthalimides/pharmacology | 2 | 100.0 |
Receptor, Epidermal Growth Factor/antagonists & inhibitors/*metabolism | 2 | 6.0 |
Recombinant Fusion Proteins/genetics/metabolism | 2 | 0.0 |
CHO Cells | 10 | 0.0 |
Cell Line, Tumor | 34 | 1.0 |
Hamsters | 15 | 0.0 |
In Vitro | 10 | 0.0 |
Recombinant Proteins/chemistry/genetics/metabolism | 2 | 0.0 |
Breast Neoplasms/*genetics | 27 | 3.0 |
Models, Genetic | 5 | 0.0 |
Receptors, Estrogen/metabolism | 10 | 3.0 |
Age Factors | 4 | 0.0 |
Down-Regulation/genetics | 2 | 3.0 |
*Gene Expression Profiling | 4 | 0.0 |
*Intracellular Signaling Peptides and Proteins | 3 | 0.0 |
*Tumor Suppressor Proteins | 5 | 0.0 |
Genome, Human | 2 | 0.0 |
Antineoplastic Agents/*pharmacology/therapeutic use | 2 | 2.0 |
Enzyme Inhibitors/*pharmacology/therapeutic use | 2 | 6.0 |
Protein-Tyrosine Kinase/*antagonists & inhibitors | 5 | 3.0 |
Breast Neoplasms/drug therapy | 2 | 6.0 |
Receptor, erbB-2/immunology/*metabolism | 4 | 44.0 |
Signal Transduction/*drug effects | 6 | 1.0 |
Antibodies, Monoclonal/*pharmacology | 2 | 1.0 |
Apoptosis | 8 | 0.0 |
Receptor, erbB-2 | 41 | 25.0 |
Adenoviridae/genetics | 2 | 0.0 |
Radiation Tolerance | 2 | 2.0 |
Tumor Stem Cell Assay | 3 | 1.0 |
Antineoplastic Agents, Hormonal/*therapeutic use | 5 | 6.0 |
Chemotherapy, Adjuvant | 6 | 2.0 |
Cohort Studies | 6 | 0.0 |
Drug Resistance | 3 | 0.0 |
Postmenopause | 5 | 2.0 |
RNA, Neoplasm/metabolism | 3 | 3.0 |
Treatment Outcome | 9 | 0.0 |
Receptors, Estrogen/*analysis | 2 | 0.0 |
Tumor Markers, Biological/genetics/*metabolism | 2 | 5.0 |
Neoplasm Invasiveness | 12 | 1.0 |
Receptor, erbB-2/analysis | 7 | 7.0 |
Epithelial Cells/pathology | 2 | 2.0 |
Mitogen-Activated Protein Kinases/*physiology | 2 | 2.0 |
Biotinylation | 2 | 1.0 |
DNA, Complementary/metabolism | 8 | 0.0 |
Immunoprecipitation | 2 | 0.0 |
NIH 3T3 Cells | 4 | 1.0 |
Receptor, erbB-2/*chemistry | 2 | 33.0 |
Ubiquitin/metabolism | 3 | 1.0 |
Retrospective Studies | 11 | 0.0 |
Risk Factors | 9 | 0.0 |
Receptor, Epidermal Growth Factor/biosynthesis/*metabolism | 3 | 13.0 |
Signal Transduction/*physiology | 8 | 0.0 |
Phosphopyruvate Hydratase/metabolism | 3 | 5.0 |
Proliferating Cell Nuclear Antigen/biosynthesis/genetics | 2 | 28.0 |
Drug Administration Schedule | 3 | 0.0 |
Gene Expression Regulation, Neoplastic/physiology | 4 | 2.0 |
Lung Neoplasms/*genetics/pathology | 3 | 3.0 |
Neoplasm Metastasis/*genetics/pathology | 2 | 20.0 |
Tumor Markers, Biological/*genetics | 3 | 2.0 |
Actins/metabolism | 4 | 0.0 |
Microfilament Proteins/metabolism | 2 | 2.0 |
Phosphoproteins/metabolism | 4 | 0.0 |
Tyrphostins/pharmacology | 6 | 4.0 |
src-Family Kinases/metabolism | 2 | 1.0 |
Fluorescent Antibody Technique | 9 | 0.0 |
Heparin/metabolism | 2 | 1.0 |
Mice, Inbred C57BL | 3 | 0.0 |
Quinazolines/pharmacology | 3 | 3.0 |
Receptor, erbB-2/antagonists & inhibitors/*metabolism | 2 | 100.0 |
Tumor Cells, Cultured/drug effects/metabolism | 2 | 1.0 |
Transfection/*methods | 2 | 3.0 |
Transgenes | 2 | 0.0 |
*Signal Transduction | 18 | 0.0 |
*Biflavonoids | 2 | 20.0 |
*Cacao | 2 | 100.0 |
Catechin/*pharmacology | 2 | 25.0 |
DNA Primers | 15 | 0.0 |
Flavonoids/pharmacology | 3 | 0.0 |
*Proanthocyanidins | 2 | 20.0 |
Receptor, erbB-2/genetics | 4 | 21.0 |
Cell Division/drug effects/physiology | 7 | 2.0 |
Cell Polarity | 2 | 1.0 |
Chimeric Proteins/metabolism | 2 | 1.0 |
*CDC2-CDC28 Kinases | 4 | 0.0 |
Mitogen-Activated Protein Kinases/metabolism/physiology | 2 | 14.0 |
Apoptosis/drug effects | 5 | 0.0 |
Endothelial Growth Factors/analysis | 2 | 2.0 |
Lymphokines/analysis | 2 | 2.0 |
Tumor Cells, Cultured/*drug effects | 2 | 4.0 |
Vascular Endothelial Growth Factors | 5 | 0.0 |
Gene Therapy/methods | 2 | 2.0 |
Liposomes | 2 | 0.0 |
Gene Expression Regulation, Developmental | 2 | 0.0 |
Mammary Glands, Animal/*metabolism | 2 | 10.0 |
Mammary Neoplasms, Animal/*metabolism | 2 | 25.0 |
Mice, Transgenic | 16 | 0.0 |
Neoplasm Recurrence, Local | 4 | 0.0 |
Receptor, erbB-3/*biosynthesis | 3 | 50.0 |
Statistics | 2 | 0.0 |
Drug Delivery Systems | 2 | 2.0 |
Enzyme Inhibitors/*therapeutic use | 3 | 3.0 |
Receptor, Epidermal Growth Factor/*antagonists & inhibitors/immunology | 2 | 25.0 |
Receptor, erbB-2/antagonists & inhibitors | 3 | 37.0 |
Cell Transformation, Neoplastic/genetics | 2 | 0.0 |
Chromosome Mapping | 23 | 0.0 |
*Chromosomes, Human, Pair 17 | 20 | 3.0 |
DNA Topoisomerases, Type II/*genetics | 6 | 46.0 |
*DNA Topoisomerases, Type II, Eukaryotic | 2 | 10.0 |
Isoenzymes/*genetics | 3 | 0.0 |
Karyotyping | 15 | 0.0 |
Metaphase | 3 | 2.0 |
Adenocarcinoma/*genetics/pathology | 3 | 3.0 |
Calibration | 3 | 2.0 |
Crosses, Genetic | 4 | 0.0 |
DNA, Neoplasm/genetics | 14 | 1.0 |
Disease Models, Animal | 8 | 0.0 |
Nucleic Acid Hybridization/*methods | 3 | 6.0 |
Breast/*physiology | 2 | 20.0 |
Breast Neoplasms/*physiopathology | 2 | 9.0 |
Databases, Factual | 2 | 0.0 |
Proteins/chemistry | 2 | 4.0 |
Alleles | 9 | 0.0 |
*Cell Transformation, Neoplastic | 5 | 1.0 |
*Genes, p53 | 7 | 1.0 |
Genotype | 5 | 0.0 |
Mammary Neoplasms, Experimental/*genetics/pathology | 2 | 33.0 |
Nucleic Acid Hybridization | 11 | 0.0 |
Base Sequence | 39 | 0.0 |
Computer Systems | 2 | 3.0 |
Lymph Nodes/metabolism | 2 | 3.0 |
RNA, Messenger/biosynthesis | 7 | 0.0 |
Tumor Markers, Biological/*analysis/genetics | 2 | 5.0 |
Breast Neoplasms/*drug therapy | 2 | 3.0 |
Cell Nucleus/metabolism | 2 | 0.0 |
Epidermal Growth Factor/metabolism | 8 | 2.0 |
Etoposide/pharmacology | 2 | 1.0 |
BRCA2 Protein | 3 | 0.0 |
Biological Markers | 2 | 0.0 |
Chi-Square Distribution | 2 | 0.0 |
Neoplasm Proteins/genetics/*metabolism | 2 | 1.0 |
Transcription Factors/genetics/*metabolism | 2 | 0.0 |
*DNA Methylation | 2 | 0.0 |
Methylation | 2 | 0.0 |
RNA, Messenger/genetics/metabolism | 3 | 0.0 |
Culture Media, Conditioned | 2 | 0.0 |
Solubility | 6 | 0.0 |
In Situ Hybridization | 9 | 0.0 |
*Nuclear Proteins | 5 | 0.0 |
Proto-Oncogene Proteins/genetics/*metabolism | 5 | 1.0 |
Epidermal Growth Factor/*metabolism | 6 | 1.0 |
Hela Cells | 3 | 0.0 |
Sequence Deletion | 3 | 0.0 |
Estrogen Receptor Modulators/pharmacology | 2 | 9.0 |
Quinazolines/*pharmacology | 5 | 5.0 |
Tamoxifen/*pharmacology | 3 | 4.0 |
Antineoplastic Agents/therapeutic use | 5 | 1.0 |
Receptor, erbB-3/*genetics | 2 | 66.0 |
Gene Expression Regulation, Neoplastic/*genetics | 2 | 1.0 |
Genes, p53/*genetics | 2 | 0.0 |
Mutation/*genetics | 2 | 0.0 |
Neoplasm Proteins/biosynthesis/*genetics | 3 | 3.0 |
Sequence Homology, Nucleic Acid | 4 | 0.0 |
Autocrine Communication | 2 | 2.0 |
Carcinoma/genetics | 2 | 6.0 |
Cyclin D1/*genetics | 2 | 3.0 |
*Genes, myc | 6 | 2.0 |
Reference Values | 3 | 0.0 |
Thyroid Gland/metabolism | 2 | 3.0 |
Antibody Specificity | 3 | 0.0 |
Carcinoma, Squamous Cell/*metabolism | 2 | 1.0 |
Cell Line, Transformed | 6 | 0.0 |
Receptor, erbB-3/metabolism | 16 | 55.0 |
Breast Neoplasms/*metabolism/*pathology | 3 | 8.0 |
Follow-Up Studies | 9 | 0.0 |
Survival Rate | 11 | 0.0 |
Subcellular Fractions | 2 | 1.0 |
Tissue Distribution | 4 | 0.0 |
Receptors, Estrogen/physiology | 3 | 10.0 |
*Peptide Library | 3 | 5.0 |
Cell Movement/physiology | 2 | 0.0 |
Recombinant Proteins/pharmacology | 4 | 0.0 |
Cadherins/*metabolism | 3 | 4.0 |
Cell Movement/drug effects | 2 | 0.0 |
Point Mutation | 4 | 0.0 |
Proteasome Endopeptidase Complex | 3 | 0.0 |
Receptors, Cell Surface/metabolism | 3 | 0.0 |
Transcription, Genetic/drug effects | 3 | 0.0 |
Chromosome Aberrations | 11 | 2.0 |
Cyclin D1/genetics | 5 | 7.0 |
DNA, Neoplasm/analysis | 13 | 1.0 |
Risk Assessment | 2 | 0.0 |
Receptor Protein-Tyrosine Kinases/*metabolism | 8 | 3.0 |
Mitogen-Activated Protein Kinase 3 | 7 | 1.0 |
Transforming Growth Factor alpha/metabolism | 3 | 4.0 |
*Genes, Tumor Suppressor | 5 | 0.0 |
Phosphoric Monoester Hydrolases/*genetics | 3 | 1.0 |
Promoter Regions (Genetics)/*genetics | 2 | 0.0 |
Tumor Suppressor Proteins/*genetics | 4 | 3.0 |
Tumor Markers, Biological/*analysis | 9 | 0.0 |
DNA Footprinting | 2 | 0.0 |
DNA-Binding Proteins/*metabolism | 4 | 0.0 |
*Enhancer Elements (Genetics) | 2 | 0.0 |
Forecasting | 2 | 0.0 |
Gene Therapy | 2 | 0.0 |
Macromolecular Substances | 7 | 0.0 |
Repetitive Sequences, Nucleic Acid | 3 | 0.0 |
Trans-Activators/*metabolism | 2 | 0.0 |
Transcription Factors/*metabolism | 3 | 0.0 |
*Adaptor Proteins, Signal Transducing | 13 | 0.0 |
Breast Neoplasms/genetics/*metabolism/pathology | 4 | 9.0 |
Oligodeoxyribonucleotides, Antisense/pharmacology | 2 | 4.0 |
Receptor, erbB-2/*genetics/metabolism | 6 | 60.0 |
Estrogen Antagonists/pharmacology | 4 | 4.0 |
Estrogens/pharmacology | 2 | 2.0 |
Receptor, erbB-2/*drug effects/genetics/metabolism | 2 | 100.0 |
Antibody Affinity | 3 | 1.0 |
Epitopes/immunology | 2 | 0.0 |
Iodine Radioisotopes | 3 | 0.0 |
Acrylamides/*chemical synthesis/chemistry/pharmacology | 2 | 50.0 |
Enzyme Inhibitors/*chemical synthesis/chemistry/pharmacology | 2 | 6.0 |
Pyrimidines/*chemical synthesis/chemistry/pharmacology | 2 | 9.0 |
Quinazolines/*chemical synthesis/chemistry/pharmacology | 2 | 28.0 |
Receptor, Epidermal Growth Factor/*antagonists & inhibitors/metabolism | 4 | 9.0 |
Transplantation, Heterologous | 8 | 0.0 |
Cadherins/metabolism | 3 | 2.0 |
Gene Expression Regulation, Neoplastic/drug effects | 3 | 0.0 |
Receptor, erbB-2/*antagonists & inhibitors/genetics | 2 | 66.0 |
Adenocarcinoma/genetics/pathology | 2 | 4.0 |
Carcinoma, Non-Small-Cell Lung/*genetics/pathology | 2 | 7.0 |
Genes, erbB-1 | 3 | 16.0 |
*Ploidies | 2 | 2.0 |
Prospective Studies | 2 | 0.0 |
Breast Neoplasms/*genetics/metabolism/pathology | 5 | 9.0 |
In Situ Hybridization, Fluorescence/*methods | 3 | 3.0 |
Reproducibility of Results | 7 | 0.0 |
Mice, Inbred ICR | 2 | 0.0 |
Mice, SCID | 6 | 0.0 |
RNA, Messenger/*genetics | 2 | 0.0 |
Central Nervous System Depressants/*pharmacology | 2 | 12.0 |
Ethanol/*pharmacology | 2 | 1.0 |
Benzoquinones/pharmacology | 2 | 25.0 |
Genes, erbB-2/*physiology | 6 | 75.0 |
Heat-Shock Proteins 70/metabolism | 3 | 5.0 |
Membrane Proteins/metabolism | 3 | 0.0 |
Molecular Chaperones/*metabolism | 3 | 5.0 |
Phosphotransferases/metabolism | 2 | 4.0 |
Protein Structure, Tertiary/physiology | 2 | 1.0 |
Drug Resistance, Neoplasm/*physiology | 2 | 6.0 |
Genes, Retinoblastoma | 2 | 2.0 |
Genes, myc | 9 | 3.0 |
*In Situ Hybridization, Fluorescence | 4 | 2.0 |
Ki-67 Antigen/analysis | 3 | 1.0 |
Receptors, Androgen/genetics | 2 | 3.0 |
Animals, Newborn | 5 | 0.0 |
Cell Communication | 2 | 0.0 |
Coculture Techniques | 3 | 0.0 |
Models, Neurological | 2 | 1.0 |
Rats, Sprague-Dawley | 5 | 0.0 |
Fibroblasts | 4 | 0.0 |
Neoplasm Proteins/*metabolism | 3 | 0.0 |
Neuregulin-1/*metabolism | 6 | 42.0 |
Cell Separation | 3 | 0.0 |
*Down-Regulation | 2 | 0.0 |
Paclitaxel/therapeutic use | 2 | 22.0 |
*Alternative Splicing | 2 | 0.0 |
Biological Transport | 2 | 0.0 |
Rabbits | 2 | 0.0 |
1-Phosphatidylinositol 3-Kinase/antagonists & inhibitors/metabolism | 2 | 2.0 |
Blotting, Southern | 25 | 0.0 |
Ca(2+)-Calmodulin Dependent Protein Kinase/metabolism | 8 | 2.0 |
Serine/metabolism | 3 | 0.0 |
Breast/*metabolism | 3 | 5.0 |
*Gene Transfer Techniques | 2 | 0.0 |
Genes, myc/genetics | 3 | 3.0 |
Loss of Heterozygosity | 3 | 0.0 |
Multivariate Analysis | 10 | 0.0 |
Breast Neoplasms/enzymology/*genetics | 2 | 7.0 |
Receptor, Epidermal Growth Factor/*genetics | 8 | 3.0 |
Sequence Alignment | 6 | 0.0 |
Antibodies, Monoclonal/therapeutic use | 4 | 2.0 |
Drug Resistance/genetics | 2 | 1.0 |
Ki-67 Antigen/biosynthesis/genetics | 2 | 40.0 |
Receptor, Epidermal Growth Factor/biosynthesis/genetics | 2 | 8.0 |
Cell Count/drug effects | 2 | 2.0 |
*Cell Death | 2 | 4.0 |
Culture Media, Serum-Free | 2 | 0.0 |
Cell Proliferation/drug effects | 3 | 3.0 |
Immunotherapy/methods | 2 | 2.0 |
Mice, Inbred NOD | 2 | 0.0 |
Oncogene Proteins v-erbB/*metabolism | 2 | 33.0 |
RNA, Neoplasm/analysis | 2 | 0.0 |
Carcinoma, Squamous Cell/*genetics/pathology | 3 | 4.0 |
Centromere/genetics | 2 | 2.0 |
Chromosomes, Human/*genetics/ultrastructure | 3 | 50.0 |
*Gene Duplication | 2 | 1.0 |
Interphase | 2 | 1.0 |
*Nucleic Acid Hybridization | 4 | 7.0 |
Paraffin Embedding | 4 | 1.0 |
Antibodies, Monoclonal | 11 | 0.0 |
Fluorescent Antibody Technique, Indirect | 4 | 0.0 |
Breast Neoplasms/metabolism/*pathology | 3 | 3.0 |
*Cell Cycle Proteins | 3 | 0.0 |
Cyclin-Dependent Kinases/metabolism | 2 | 0.0 |
Proto-Oncogene Proteins c-myc/metabolism | 2 | 2.0 |
Cytoplasm/metabolism | 2 | 0.0 |
Protein-Serine-Threonine Kinases/*metabolism | 3 | 0.0 |
*ADP Ribose Transferases | 6 | 7.0 |
*Bacterial Toxins | 4 | 2.0 |
*Virulence Factors | 7 | 8.0 |
Breast/metabolism | 2 | 2.0 |
Heterozygote | 5 | 0.0 |
Proto-Oncogene Proteins/genetics | 9 | 1.0 |
*Oncogenes | 14 | 3.0 |
Receptor, erbB-2/*antagonists & inhibitors/immunology | 3 | 100.0 |
Breast Neoplasms/*genetics/metabolism | 7 | 6.0 |
Receptor, Epidermal Growth Factor/biosynthesis | 2 | 4.0 |
Glycoproteins/*metabolism | 7 | 3.0 |
Protein p53/*metabolism | 3 | 0.0 |
Tumor Markers, Biological/*metabolism | 4 | 0.0 |
Cell Movement | 3 | 0.0 |
*Proteins | 2 | 0.0 |
Receptors, Estrogen/genetics | 2 | 3.0 |
Recombinant Proteins/chemistry/metabolism | 5 | 0.0 |
Spodoptera | 2 | 0.0 |
Chromosomes, Human/*genetics | 2 | 4.0 |
Cell Proliferation | 3 | 1.0 |
Electrophoresis, Gel, Two-Dimensional | 2 | 0.0 |
Luciferases/metabolism | 2 | 0.0 |
Luminescent Proteins/metabolism | 2 | 0.0 |
Protein Synthesis Inhibitors/pharmacology | 2 | 0.0 |
Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2 | 0.0 |
Antigens, Differentiation/metabolism | 2 | 1.0 |
Microscopy, Electron | 3 | 0.0 |
*Gene Therapy | 4 | 1.0 |
Cell Division/genetics | 2 | 0.0 |
Cell Transformation, Neoplastic/*genetics | 4 | 2.0 |
DNA, Neoplasm/*genetics | 7 | 3.0 |
Bladder/cytology/*metabolism/pathology | 2 | 66.0 |
Epidermal Growth Factor/genetics/metabolism/*physiology | 2 | 40.0 |
Mice, Inbred Strains | 2 | 0.0 |
Mitogens/pharmacology | 2 | 0.0 |
Muscle, Smooth/cytology/*metabolism/pathology | 2 | 100.0 |
Urethral Obstruction/*metabolism/pathology | 2 | 100.0 |
Gene Expression/drug effects | 3 | 0.0 |
DNA/biosynthesis | 2 | 0.0 |
Receptor, erbB-2/chemistry/drug effects/*metabolism | 2 | 100.0 |
DNA, Neoplasm | 2 | 1.0 |
Receptor, Epidermal Growth Factor/analysis/biosynthesis | 2 | 40.0 |
Colonic Neoplasms/*enzymology/pathology | 2 | 16.0 |
Isoenzymes/*metabolism | 2 | 0.0 |
Protein-Tyrosine Kinase/*metabolism | 2 | 0.0 |
Biopsy, Needle | 2 | 0.0 |
Chromosomes, Human, Pair 17 | 5 | 1.0 |
Neoplasm Proteins/metabolism | 3 | 0.0 |
Fibroblast Growth Factors/genetics | 2 | 5.0 |
Neoplasm Proteins/genetics | 3 | 0.0 |
Breast Neoplasms/*enzymology/metabolism/pathology | 2 | 25.0 |
Breast Neoplasms/*genetics/pathology | 10 | 4.0 |
*Gene Deletion | 4 | 0.0 |
Isoenzymes/metabolism | 2 | 0.0 |
Cell Compartmentation/physiology | 2 | 5.0 |
DNA, Complementary | 3 | 0.0 |
Neuregulins | 14 | 24.0 |
Receptor, erbB-2/analysis/genetics/metabolism | 2 | 100.0 |
1-Phosphatidylinositol 3-Kinase/*physiology | 3 | 5.0 |
Ca(2+)-Calmodulin Dependent Protein Kinase/*physiology | 2 | 8.0 |
Glycoproteins/*pharmacology | 5 | 5.0 |
*Mitogen-Activated Protein Kinases | 3 | 0.0 |
Protein-Tyrosine Kinase/metabolism | 11 | 1.0 |
Protein Kinase C/*metabolism | 2 | 0.0 |
Piperazines/therapeutic use | 2 | 10.0 |
Pyrimidines/therapeutic use | 2 | 9.0 |
Cytoplasm/enzymology | 2 | 2.0 |
Sequence Analysis, DNA | 3 | 0.0 |
Genes, Reporter | 4 | 0.0 |
Genetic Vectors/*genetics | 2 | 2.0 |
Receptor, erbB-2/biosynthesis/*genetics | 5 | 71.0 |
Recombinant Fusion Proteins/physiology | 2 | 0.0 |
Receptor, Epidermal Growth Factor/antagonists & inhibitors | 2 | 5.0 |
Recombinant Proteins/genetics/metabolism | 2 | 0.0 |
Tumor Cells, Cultured/physiology | 2 | 10.0 |
Receptor, Epidermal Growth Factor/chemistry/*metabolism | 3 | 8.0 |
Carrier Proteins/*pharmacology | 2 | 4.0 |
*Neuregulin-1 | 13 | 50.0 |
Proto-Oncogene Proteins/analysis/*biosynthesis | 2 | 8.0 |
Receptor, Epidermal Growth Factor/analysis/*biosynthesis | 3 | 13.0 |
Receptor, erbB-2/analysis/*biosynthesis | 2 | 33.0 |
Growth Substances/*metabolism | 3 | 2.0 |
Protein Binding/genetics | 2 | 0.0 |
Proteins/metabolism | 8 | 0.0 |
Receptor, Epidermal Growth Factor/*genetics/metabolism | 2 | 3.0 |
*Transcription Factors | 2 | 0.0 |
Receptor, erbB-2/physiology | 3 | 37.0 |
Transforming Growth Factor alpha/*pharmacology | 2 | 3.0 |
Receptor, erbB-2/immunology | 3 | 33.0 |
Rats, Inbred F344 | 2 | 0.0 |
Sialoglycoproteins/metabolism | 2 | 4.0 |
Exons | 4 | 0.0 |
RNA/genetics | 2 | 1.0 |
Ca(2+)-Calmodulin Dependent Protein Kinase/*metabolism | 2 | 0.0 |
Oligonucleotides, Antisense/pharmacology | 4 | 1.0 |
Enzyme Activation/drug effects | 8 | 0.0 |
Growth Substances/physiology | 2 | 1.0 |
Receptor, Epidermal Growth Factor/metabolism/*physiology | 2 | 12.0 |
Receptors, Growth Factor/metabolism | 2 | 1.0 |
Carcinoma/*genetics | 2 | 1.0 |
Gastrointestinal Neoplasms/*genetics | 2 | 6.0 |
Gene Amplification/*genetics | 10 | 9.0 |
Genetic Markers | 9 | 0.0 |
Hybrid Cells | 3 | 0.0 |
Receptor, erbB-2/biosynthesis/genetics/immunology | 2 | 100.0 |
Ki-67 Antigen/metabolism | 6 | 2.0 |
Pancreatic Neoplasms/*pathology | 2 | 5.0 |
Protein p53/analysis | 3 | 1.0 |
Carcinoma | 2 | 5.0 |
NF-kappa B/metabolism | 2 | 0.0 |
Neurofibromin 1 | 2 | 1.0 |
Adenocarcinoma/*genetics | 3 | 2.0 |
Genes, myc/*genetics | 2 | 2.0 |
Proto-Oncogene Proteins/*genetics | 14 | 1.0 |
Stomach Neoplasms/*genetics | 4 | 3.0 |
*Tumor Cells, Cultured | 2 | 2.0 |
*Polymerase Chain Reaction | 2 | 0.0 |
Age of Onset | 2 | 0.0 |
Intercellular Signaling Peptides and Proteins/metabolism/*pharmacology | 2 | 50.0 |
Receptor, Epidermal Growth Factor/drug effects/metabolism | 2 | 4.0 |
Receptor, erbB-2/drug effects/metabolism | 3 | 37.0 |
Signal Transduction/*drug effects/physiology | 2 | 3.0 |
Cell Membrane/chemistry | 3 | 2.0 |
Protein Structure, Secondary | 4 | 0.0 |
Receptor, erbB-2/metabolism/*physiology | 4 | 66.0 |
Chromosome Aberrations/*genetics | 2 | 1.0 |
Chromosome Banding | 5 | 0.0 |
Chromosome Disorders | 5 | 1.0 |
DNA Probes/genetics | 2 | 1.0 |
Deoxyribonucleases, Type II Site-Specific/metabolism | 2 | 1.0 |
Genes, Structural, Neoplasm | 2 | 13.0 |
Epithelial Cells/metabolism | 2 | 0.0 |
Breast Neoplasms/epidemiology/*genetics/pathology | 2 | 25.0 |
Incidence | 2 | 0.0 |
Fluorouracil/administration & dosage | 2 | 1.0 |
*Gene Expression Regulation, Neoplastic/drug effects | 2 | 3.0 |
Protein p53/*analysis | 2 | 1.0 |
*Cell Division | 2 | 1.0 |
Combined Modality Therapy | 3 | 0.0 |
Carrier Proteins/*metabolism | 5 | 0.0 |
Neoplasm Invasiveness/*genetics | 2 | 5.0 |
Neoplasm Metastasis/*genetics | 3 | 5.0 |
Pseudopodia/metabolism | 3 | 10.0 |
Binding Sites, Antibody | 3 | 0.0 |
Protein Folding | 2 | 0.0 |
*Adaptor Proteins, Vesicular Transport | 5 | 1.0 |
Proteins/*metabolism | 2 | 0.0 |
*Chromosome Deletion | 3 | 0.0 |
Esophageal Neoplasms/*genetics | 3 | 4.0 |
Epithelial Cells/*metabolism | 4 | 3.0 |
Growth Substances/metabolism | 3 | 2.0 |
Receptor, Epidermal Growth Factor/genetics/metabolism | 4 | 7.0 |
Receptor, erbB-3/genetics/metabolism | 3 | 75.0 |
Reverse Transcriptase Polymerase Chain Reaction/methods | 3 | 0.0 |
Carcinoma/*metabolism | 2 | 2.0 |
Ovarian Neoplasms/*metabolism/pathology | 3 | 4.0 |
Oncogenes | 9 | 3.0 |
*Zebrafish Proteins | 2 | 0.0 |
Gene Expression/genetics | 2 | 0.0 |
Transforming Growth Factor alpha/pharmacology | 3 | 3.0 |
Carcinoma, Squamous Cell/metabolism | 2 | 3.0 |
Receptor, Epidermal Growth Factor/*biosynthesis | 4 | 3.0 |
Immunoglobulin Fragments/*immunology | 2 | 14.0 |
Ovarian Neoplasms | 2 | 5.0 |
Tumor Markers, Biological/analysis | 3 | 0.0 |
Fluorescence Resonance Energy Transfer | 2 | 4.0 |
Green Fluorescent Proteins | 2 | 0.0 |
Plasmids/metabolism | 2 | 0.0 |
*Protein Conformation | 2 | 0.0 |
Receptor, erbB-2/chemistry/*metabolism | 3 | 33.0 |
Electrophoresis, Polyacrylamide Gel | 3 | 0.0 |
*Translocation, Genetic | 3 | 0.0 |
Cysteine Endopeptidases/*metabolism | 2 | 0.0 |
Rifabutin/*analogs & derivatives/*pharmacology | 4 | 36.0 |
Colorectal Neoplasms/pathology | 2 | 14.0 |
Mucins/analysis | 2 | 5.0 |
Genes, ras | 3 | 1.0 |
Proto-Oncogene Proteins c-myc/genetics | 2 | 3.0 |
DNA Probes | 11 | 1.0 |
Genes, Tumor Suppressor | 8 | 0.0 |
Carcinoma, Ductal, Breast/*genetics/pathology | 2 | 7.0 |
Chromosome Deletion | 4 | 0.0 |
DNA, Neoplasm/isolation & purification | 3 | 10.0 |
*Milk Proteins | 2 | 0.0 |
Proto-Oncogene Proteins/drug effects/genetics/*metabolism | 2 | 22.0 |
Down-Regulation/drug effects | 3 | 1.0 |
Antibodies, Monoclonal/immunology/therapeutic use | 2 | 10.0 |
Oncogenes/*genetics | 5 | 6.0 |
Organ Specificity | 2 | 0.0 |
*Transcription, Genetic | 3 | 0.0 |
Breast Neoplasms/classification/*genetics/pathology | 2 | 40.0 |
Epidermal Growth Factor/metabolism/*pharmacology | 3 | 4.0 |
Chromosomes, Human, Pair 11 | 4 | 1.0 |
Transforming Growth Factor beta/*metabolism | 2 | 0.0 |
Estradiol/*pharmacology | 2 | 0.0 |
Linkage (Genetics) | 3 | 0.0 |
Phosphotyrosine/metabolism | 5 | 1.0 |
Aneuploidy | 6 | 3.0 |
Gene Deletion | 5 | 0.0 |
Ploidies | 3 | 1.0 |
Chimeric Proteins | 2 | 2.0 |
Luciferases/genetics | 2 | 0.0 |
Crystallography, X-Ray | 3 | 0.0 |
Receptor Aggregation | 2 | 2.0 |
Adenocarcinoma/*enzymology/pathology | 2 | 22.0 |
Cell Differentiation/drug effects | 2 | 0.0 |
Enzyme Induction/drug effects | 2 | 0.0 |
Epithelial Cells | 4 | 0.0 |
Protein Processing, Post-Translational | 2 | 0.0 |
Receptors, Estrogen/analysis | 7 | 2.0 |
Receptors, Progesterone/analysis | 5 | 2.0 |
*Cell Cycle | 2 | 0.0 |
Mammary Glands, Animal/pathology | 2 | 33.0 |
Adenocarcinoma/metabolism/pathology | 3 | 5.0 |
Calcium/metabolism | 2 | 0.0 |
Carcinoma, Squamous Cell | 2 | 1.0 |
Recombinant Proteins | 2 | 0.0 |
Receptor, Epidermal Growth Factor/*analysis | 4 | 1.0 |
Breast Neoplasms/drug therapy/*genetics/pathology | 2 | 28.0 |
Estradiol/*analogs & derivatives/pharmacology | 2 | 4.0 |
Tamoxifen/*analogs & derivatives/pharmacology | 2 | 8.0 |
Signal Transduction/drug effects/*physiology | 2 | 0.0 |
Genes, p53 | 4 | 0.0 |
DNA, Neoplasm/analysis/genetics | 2 | 2.0 |
Immunotherapy | 2 | 0.0 |
Receptor, erbB-2/biosynthesis | 3 | 12.0 |
Antigens, Neoplasm/metabolism | 2 | 2.0 |
Mucins/*metabolism | 4 | 4.0 |
Ovarian Neoplasms/*genetics | 4 | 1.0 |
BRCA1 Protein | 3 | 2.0 |
DNA, Neoplasm/*analysis | 2 | 1.0 |
Polymorphism, Single-Stranded Conformational | 2 | 0.0 |
Proto-Oncogenes | 5 | 2.0 |
Transcription Factors/genetics | 3 | 0.0 |
Estradiol/pharmacology | 4 | 1.0 |
Oncogenes/genetics | 3 | 4.0 |
Immunoglobulin Variable Region | 2 | 8.0 |
Fluorouracil/pharmacology | 2 | 3.0 |
Chromosomes, Human, Pair 16 | 3 | 2.0 |
DNA Topoisomerases, Type II, Eukaryotic/*genetics | 2 | 25.0 |
Gene Amplification/genetics | 3 | 5.0 |
Species Specificity | 2 | 0.0 |
Breast Neoplasms/*chemistry/pathology | 2 | 3.0 |
Fibroblast Growth Factors/*genetics | 2 | 4.0 |
Breast Neoplasms/genetics/*metabolism | 4 | 6.0 |
Estrogen Antagonists/*pharmacology | 2 | 2.0 |
RNA, Messenger/genetics | 9 | 0.0 |
RNA, Neoplasm/genetics | 5 | 1.0 |
1-Phosphatidylinositol 3-Kinase | 3 | 2.0 |
Immunotoxins/pharmacology | 2 | 16.0 |
Phosphotransferases (Alcohol Group Acceptor)/metabolism | 2 | 2.0 |
Restriction Mapping | 5 | 0.0 |
Breast Neoplasms/etiology/*genetics | 2 | 6.0 |
Gastric Mucosa/pathology | 2 | 5.0 |
*Point Mutation | 2 | 0.0 |
Polymerase Chain Reaction/methods | 2 | 0.0 |
Polymorphism, Restriction Fragment Length | 9 | 0.0 |
Stomach Neoplasms/*genetics/pathology | 2 | 4.0 |
Neoplasm Proteins/*biosynthesis/genetics | 2 | 1.0 |
Receptor, erbB-2/*biosynthesis/genetics | 2 | 25.0 |
*Breast Neoplasms | 3 | 15.0 |
Carrier Proteins/genetics | 2 | 0.0 |
Glycoproteins/genetics | 2 | 2.0 |
Neoplasms/*drug therapy/metabolism | 2 | 8.0 |
*Proto-Oncogenes | 19 | 2.0 |
Tamoxifen/pharmacology | 2 | 2.0 |
RNA, Neoplasm/*analysis | 2 | 4.0 |
Phosphotyrosine | 3 | 1.0 |
Proto-Oncogene Proteins/*physiology | 2 | 0.0 |
Tyrosine/analogs & derivatives/metabolism | 3 | 2.0 |
Genes, p53/genetics | 3 | 1.0 |
Neoplasm Metastasis/genetics | 2 | 4.0 |
*Chromosomes, Human, Pair 1 | 2 | 0.0 |
Cricetulus | 3 | 0.0 |
Neuroblastoma/*genetics | 2 | 2.0 |
Immunologic Techniques | 2 | 0.0 |
Case-Control Studies | 4 | 0.0 |
Gene Expression Regulation/*physiology | 2 | 0.0 |
Cyclin D1/*metabolism | 2 | 3.0 |
Gene Frequency | 2 | 0.0 |
Neoplasm Proteins/*genetics | 2 | 0.0 |
Tamoxifen/therapeutic use | 2 | 3.0 |
Proto-Oncogenes/*genetics | 4 | 5.0 |
Proto-Oncogene Proteins/analysis | 3 | 1.0 |
DNA Primers/genetics | 2 | 0.0 |
Antineoplastic Agents/pharmacology/therapeutic use | 2 | 6.0 |
Neoplasms/drug therapy/metabolism | 2 | 11.0 |
Morphogenesis | 2 | 0.0 |
Conserved Sequence | 2 | 0.0 |
Receptor, Epidermal Growth Factor/*analysis/biosynthesis | 2 | 22.0 |
Breast Neoplasms/*chemistry/genetics | 2 | 15.0 |
Lactams, Macrocyclic | 2 | 100.0 |
MAP Kinase Signaling System/drug effects | 2 | 2.0 |
DNA, Neoplasm/genetics/isolation & purification | 3 | 2.0 |
Receptors, Estrogen/biosynthesis | 3 | 6.0 |
Carcinoma, Squamous Cell/*genetics | 4 | 2.0 |
Variation (Genetics) | 2 | 0.0 |
Ovarian Neoplasms/*genetics/pathology | 2 | 2.0 |
Genetic Markers/genetics | 2 | 0.0 |
*Bile Ducts, Intrahepatic | 2 | 6.0 |
*Multigene Family | 2 | 0.0 |
Carcinoma/*genetics/pathology | 2 | 3.0 |
Neuregulin-1/*pharmacology | 4 | 23.0 |
Epithelium/pathology | 2 | 1.0 |
Cyclin D1/metabolism | 2 | 1.0 |
Proto-Oncogene Proteins c-bcl-2/metabolism | 2 | 0.0 |
Retinoblastoma Protein/metabolism | 2 | 0.0 |
Germany | 2 | 0.0 |
Receptors, Cell Surface/*metabolism | 2 | 0.0 |
Antibodies, Monoclonal/administration & dosage | 2 | 6.0 |
Melanoma/pathology | 2 | 6.0 |
*Polymorphism, Restriction Fragment Length | 2 | 0.0 |
Insulin-Like Growth Factor I/*metabolism | 2 | 1.0 |
Epidermal Growth Factor/genetics | 2 | 2.0 |
Protein-Tyrosine Kinase/*genetics | 2 | 0.0 |
Receptor, erbB-2/*antagonists & inhibitors/metabolism | 2 | 25.0 |
Cyclin D1/biosynthesis | 2 | 4.0 |
Signal Transduction/genetics | 2 | 0.0 |
Protein-Tyrosine Kinase/genetics | 2 | 1.0 |
Lung Neoplasms/genetics | 2 | 3.0 |
Actins/genetics | 2 | 1.0 |
Platelet-Derived Growth Factor/genetics | 2 | 6.0 |
Pancreatic Neoplasms/genetics | 2 | 5.0 |
RNA, Messenger/*metabolism | 2 | 0.0 |
Astrocytoma/*genetics | 2 | 4.0 |
Double-Blind Method | 2 | 0.0 |
Nitriles/*therapeutic use | 2 | 33.0 |
Triazoles/*therapeutic use | 2 | 28.0 |
Receptor, erbB-2/deficiency/genetics/*physiology | 2 | 100.0 |
Algorithms | 2 | 0.0 |
Expressed Sequence Tags | 2 | 0.0 |
Gene Expression Profiling/*methods | 2 | 2.0 |
Oligonucleotide Array Sequence Analysis/*methods | 2 | 1.0 |
*Signal Transduction/drug effects | 2 | 2.0 |
DNA/metabolism | 2 | 0.0 |
Molecular Weight | 2 | 0.0 |
Mitogen-Activated Protein Kinase Kinases/metabolism | 2 | 1.0 |
Receptor, erbB-2/antagonists & inhibitors/*physiology | 2 | 50.0 |
Esophageal Neoplasms/*genetics/pathology | 2 | 6.0 |
Quality Control | 2 | 1.0 |
*Genes, Structural | 3 | 0.0 |
Ki-67 Antigen/biosynthesis | 2 | 2.0 |
Receptors, Progesterone/biosynthesis | 2 | 6.0 |
Rifabutin/*analogs & derivatives/pharmacology | 2 | 50.0 |
Introns | 2 | 0.0 |
*Promoter Regions (Genetics) | 2 | 0.0 |
Cell Death | 2 | 0.0 |
Hydrogen Bonding | 2 | 1.0 |
Cyclins/*metabolism | 2 | 0.0 |
Cytoskeletal Proteins/*metabolism | 2 | 1.0 |
Cytoskeletal Proteins/metabolism | 2 | 0.0 |
DNA-Binding Proteins/metabolism | 2 | 0.0 |
Trans-Activators/metabolism | 3 | 0.0 |
DNA-Binding Proteins/genetics | 2 | 0.0 |
Protein p53/metabolism | 2 | 0.0 |
Drug Combinations | 2 | 0.0 |
Bladder Neoplasms/*genetics | 2 | 2.0 |
MAP Kinase Kinase 1 | 2 | 1.0 |
Neuregulin-1/genetics/*metabolism | 2 | 100.0 |
